Biography:
Dr. Amirhosein Maali is a Ph.D. graduate of the Pasteur Institute of Iran and a faculty member in the Department of Biotechnology at Qazvin University of Medical Sciences. His academic work focuses on cancer immunotherapy, particularly the design and development of antibody-fragment based platforms and CAR-T cell technologies for hematologic malignancies.
His research interests include the engineering of targeted cellular immunotherapies, the use of antibody fragments and nanobodies for tumor antigen recognition, and the development of modular CAR-T cell strategies. More recently, his work has involved the development of universal modular CAR T-cell platforms using target-specific nanobodies, with the aim of improving flexibility and target adaptability in cellular immunotherapy.
In addition to his academic role, he is the founder and CEO of DNAGen Biotechnology Company, which works in the field of biotechnology and the development of diagnostic and immunodiagnostic platforms.
Recent updates on application of modular universal CAR-T cell therapies in cancer